Peil Biomedical Subsidiary Receives NMPA Approval for Phase I Clinical Trial of RA Drug PP011 in China
Key facts
- Peil Biomedical Subsidiary Receives NMPA Approval for Phase I Clinical Trial of RA Drug PP011 in China
- Peil Biomedical announced that its wholly-owned subsidiary, Peil (Shanghai) Pharmaceutical Technology, has received approval from China's National Medical Products Administration (NMPA) to conduct Phase I clinical trials for its oral new drug PP011, intended for rheumatoid arthritis (RA). The trial is expected to be completed by Q1 2027.
- Source: PR Times
- Date: June 2, 2026
Direct answer
Peil Biomedical announced that its wholly-owned subsidiary, Peil (Shanghai) Pharmaceutical Technology, has received approval from China's National Medical Products Administration (NMPA) to conduct Phase I clinical trials for its oral new drug PP011, intended for rheumatoid arthritis (RA). The trial is expected to be completed by Q1 2027.
- Citation
- Peil Biomedical Subsidiary Receives NMPA Approval for Phase I Clinical Trial of RA Drug PP011 in China (June 2, 2026), PR Times
- Source
- PR Times
- Date
- June 2, 2026
Peil Biomedical announced that its wholly-owned subsidiary, Peil (Shanghai) Pharmaceutical Technology, has received approval from China's National Medical Products Administration (NMPA) to conduct Phase I clinical trials for its oral new drug PP011, intended for rheumatoid arthritis (RA). The trial is expected to be completed by Q1 2027.
📋 Article Processing Timeline
- 📰 Published: June 2, 2026 at 09:00
- 🔍 Collected: June 3, 2026 at 08:00 (23h 0m after Published)
- 🤖 AI Analyzed: June 7, 2026 at 06:57 (94h 56m after Collected)
1. Date of Occurrence: 2026/06/02
2. New Drug Name or Code: PP011
3. Purpose: Rheumatoid Arthritis (RA)
4. Planned Development Stages: Phase I clinical trial, Phase II clinical trial, Phase III clinical trial, and new drug registration review.
5. Current Development Phase: The company has received approval from China's National Medical Products Administration (NMPA) to conduct Phase I clinical trials for healthy volunteers.
6. Next Development Stage: Expected to complete Phase I clinical trial in Q1 2027.
7. Market Condition: The global rheumatoid arthritis (RA) market is in a growth phase. According to IMARC Group, the market scale is expected to reach $35.4 billion by 2035. Current treatments mainly consist of biologics, which are injectable. Oral drugs offer a solution to the inconvenience of injections, although existing oral options have side effects.
2. New Drug Name or Code: PP011
3. Purpose: Rheumatoid Arthritis (RA)
4. Planned Development Stages: Phase I clinical trial, Phase II clinical trial, Phase III clinical trial, and new drug registration review.
5. Current Development Phase: The company has received approval from China's National Medical Products Administration (NMPA) to conduct Phase I clinical trials for healthy volunteers.
6. Next Development Stage: Expected to complete Phase I clinical trial in Q1 2027.
7. Market Condition: The global rheumatoid arthritis (RA) market is in a growth phase. According to IMARC Group, the market scale is expected to reach $35.4 billion by 2035. Current treatments mainly consist of biologics, which are injectable. Oral drugs offer a solution to the inconvenience of injections, although existing oral options have side effects.
FAQ
What is Peil Biomedical's PP011?
It is an oral new drug candidate for rheumatoid arthritis (RA).
What is the clinical trial status?
Approved by China's NMPA for Phase I trials, expected to be completed in Q1 2027.
Why develop an oral drug?
To address the inconvenience of current injectable biologics for RA treatment.